With the prosperity of innovative drugs, new challenges will be presented in this field

In the past, most of the pharmaceutical product market in China was dominated by generic drugs.
In recent years, with the advancement of policies such as consistency evaluation, mass procurement, and accelerated review of new drugs, China’s pharmaceutical industry has accelerated its transformation and upgrading, gradually shifting from generic drugs to innovative drugs.
, The transformation of the direction of improved new drugs has made the market for innovative drugs increasingly prosperous
.
In the context of the continuous expansion of demand for innovative drug R&D and commercial production, it is expected that new challenges will also be presented to the upstream pharmaceutical equipment field
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) Innovative medicine industry is booming.
Since 2021, there has been continuous financing news in the field of innovative medicines, which shows that innovative medicines are being favored by the market
.
According to data from Southwest Securities, in the first half of this year, in the field of innovative drugs, there were 8 financing events exceeding RMB 500 million, accounting for 5.
9%; there were 45 financing events exceeding RMB 100 million, accounting for 33.
3%
.
In addition, in the first half of the year, there were 4 large financing events of more than 1 billion yuan.
Among them, the performance was particularly outstanding.
The company announced in June this year that it had completed a financing line of 1.
2 billion yuan.
This round of financing was funded by China Merchants Health, Sequoia Capital China Fund, Jinglin Investment, WuXi AppTec jointly led the investment, and professional medical and health investment institutions such as Aobo Capital, E Fund Capital CITIC Securities Investment and other professional medical and health investment institutions followed the investment
.
At the same time, talents are also accelerating the influx of local innovative drug companies during the year to help the research and development of domestic innovative drugs
.
For example, Dr.
Joseph E.
Eid, a medical talent, announced that he would join Hengrui Pharmaceuticals in October as executive vice president, chief medical officer and head of global drug development; Dong Lijun, former general manager of AstraZeneca China’s digestion and product development business department, In August, Luoxin Pharmaceutical posted an announcement, and he was appointed as the group's executive vice president and chief operating officer; on June 8, Qian Wei, general manager of the first oncology division of Roche Pharmaceuticals, announced that he would become the chief commercial officer of Junshi Biotech.
Responsible for the company's commercialization planning and business operations
.
Behind the fact that the executives of these multinational pharmaceutical companies have left their posts to join local pharmaceutical companies, it can be seen that China's innovative drug market is developing rapidly and has promising prospects
.
Affected by factors such as accelerated approval of new drugs, increased capital, and the influx of talents, domestic innovative drug products continue to be approved for listing
.
According to statistics, in the first half of 2021 alone, 19 domestic new drugs were approved, which is close to the number approved throughout the previous year.

.
Many institutions are also optimistic about the future development of innovative drugs
.
Among them, Huatai Securities believes that thanks to the policy support and capital promotion in the past few years, the domestic pharmaceutical industry, especially the innovative drug industry, has performed prosperously.
It is expected that the pattern of innovative drug research and development is expected to continue to improve in the future
.
In addition, Tianding Securities is also optimistic about the investment opportunities of innovative drugs in the pharmaceutical industry
.
The pharmaceutical equipment field is facing new challenges.
With the increasingly prosperous trend of innovative drugs, the R&D and commercial production needs of pharmaceutical companies may continue to expand, and higher requirements for the speed and flexibility of production line construction will be put forward.
At the same time, the upstream pharmaceutical equipment field It will also face new challenges
.
On the one hand, under the influence of medical insurance negotiations and centralized procurement, the price of innovative drugs is facing a downward trend as a whole
.
At present, China has conducted five rounds of medical insurance drug negotiations for innovative drugs, and the average drop of innovative drugs included in the medical insurance for the first time has basically been nearly half
.
Among them, in the national medical insurance negotiations in 2020, the average price reduction of PD-1 products is as high as 78%
.
Therefore, in the future, innovative drug companies will face challenges in cost control, and the localization of pharmaceutical equipment is imminent
.
At present, most of China's pharmaceutical equipment is still in the low-end field, and it is urgent to upgrade to the mid-to-high-end direction, break the situation of dependence on imports, and reduce the cost of pharmaceutical companies
.
On the other hand, the homogeneity of some popular innovative drug products is serious, and the medical insurance negotiations have further shortened the life cycle of innovative drugs.
In the case of increasingly fierce market competition, for innovative drug companies, once the product is approved in the market After entering the market, it is necessary to accelerate the process of product commercialization, which also puts forward new requirements for equipment production capacity and stable supply
.
Pharmaceutical equipment companies need to seize the opportunity, increase investment in innovation, and continue to upgrade equipment to meet the capacity needs of innovative drug companies
.